SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of tradipitant for motion sickness, marking the first new treatment in decades. This milestone, combined with promising Phase 2 data showing tradipitant's efficacy in reducing GLP-1 induced nausea and vomiting, has ignited widespread community discussion about its significant potential in a rapidly expanding market. Investors are also keenly anticipating upcoming regulatory decisions for other pipeline candidates, fueling speculation about substantial growth and future acquisition interest.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending due to its recent loan agreement, which aims to secure capital without immediate equity dilution, and the planned distribution of a "Dream Bowl 2026 Meme Coin" dividend tied to its Datavault AI partnership. Community sentiment is highly polarized: many foresee a significant short squeeze and value creation from tokenization and potential asset sales, while a vocal segment views these developments as further distractions by a management team perceived as eroding shareholder value. The broader context involves the company's foray into AI-driven Real-World Asset tokenization, alongside ongoing scrutiny of its core biotech pipeline.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending following the recent FDA approval of FUROSCIX for pediatric use and new patents issued for its ReadyFlow Autoinjector, which the community views as a significant advancement for at-home fluid management. While optimism surrounds these developments and the anticipated Afrezza launch in India, a persistent debate centers on current management's ability to translate product success into substantial long-term shareholder value.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid notable Bitcoin volatility and a mixed outlook driven by fluctuating ETF inflows and the impending Bank of Japan rate decision. The community is sharply divided between those anticipating a prolonged 'crypto winter' and others who see the current dips as a prime 'buy the dip' opportunity driven by continued whale accumulation and institutional interest. This divergence in sentiment underscores the ongoing debate about Bitcoin's predictable cyclical behavior versus its increasing integration into traditional finance through instruments like IBIT.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility and increased trading activity as the anticipated FDA decision for its Relacorilant treatment for Cushing's Syndrome approaches. A sharp price decline fuels community fears of potential regulatory hurdles and whispers of a Complete Response Letter, while many longs emphasize the company's robust pipeline and accuse shorts of manipulation, making its near-term outlook a major point of contention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Meta said in an announcement that the Manus agent will unlock opportunities for businesses across its products.</li><li>Manus’ team will also join Meta’s but the company will continue to operate from Singapore.</li><li>Meta said that it will continue to operate and sell the Manus service while also integrating it into its products including Meta AI and scaling the service to more businesses.</li></ul><p><br>Meta Platforms (META) on Monday said that it has agreed to acquire Singapore-based tech startup Manus for an undisclosed sum.</p><p>Manus is focused on building a general-purpose AI agent designed to help users tackle research, automation, and complex tasks.</p><h2 class="st-heading-2">Why Is Meta Buying Manus?</h2><p>Meta <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/business/news/manus-joins-meta-accelerating-ai-innovation-for-businesses">said</a> in an announcement that the Manus will unlock opportunities for businesses across its products. The company’s autonomous general purpose agent can independently execute complex tasks like market research, coding, and data analysis, Meta added.</p><p>Meta said that it will continue to operate and sell the Manus service while also integrating it into its products and scaling the service to more businesses.</p><p>Manus’ team will also join Meta’s but the company will continue to operate from Singapore. It will also continue to sell and operate its product subscription service through its app and website.</p><p>“Joining Meta allows us to build on a stronger, more sustainable foundation without changing how Manus works or how decisions are made,” said Manus CEO Xiao Hong. The company said earlier this month that its annual run rate for revenue is over $125 million including usage-based and other revenue, merely eight months after launching its first general AI agent. Prior to the launch, it raised $75 million led by Benchmark.</p><p>META traded 0.3% lower after hours on Monday at the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around META stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.</p><figure class="image"><img style="aspect-ratio:586/58;" src="data:image/png;base64,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" alt="META’s Sentiment Meter and Message Volume as of 6:12 p.m. ET on Dec. 29, 2025 | Source: Stocktwits" width="586" height="58"><figcaption>META’s Sentiment Meter and Message Volume as of 6:12 p.m. ET on Dec. 29, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/META">META stock</a> has gained 13% this year and by about 11% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

The Meta logo is displayed during the Viva Technology show at Parc des Expositions Porte de Versailles on May 22, 2024 in Paris, France. (Photo by Chesnot/Getty Images)

Meta Acquires Singapore-Based Startup To Enhance AI-Capability For Undisclosed Sum

Manus is focused on building a general-purpose AI agent designed to help users tackle research, automation, and complex tasks.

Equity

Manus is focused on building a general-purpose AI agent designed to help users tackle research, automation, and complex tasks.


<ul class="summary-bullets"><li>Citi, Truist, and Stifel have maintained a “Buy” rating on the stock.</li><li>Citi analyst Atif Malik viewed Nvidia's licensing deal with Groq as a "clear positive.”</li><li>Truist said the reported $20 billion cost is high, but it is small relative to Nvidia's cash position and cash flow generation.</li></ul><p>Nvidia’s stock was in focus on Monday after several top brokerages voiced their confidence in the chipmaker’s $20 billion licensing deal with AI chip startup Groq, saying that it could extend its leadership in the AI infrastructure space.</p><p>Analysts at Truist said that Nvidia's licensing agreement with Groq is intended to "fortify" its competitive positioning in inference versus tensor processing units, per TheFly. While the reported $20 billion cost is high, it is small relative to Nvidia's cash position and cash flow generation. The firm kept a “Buy” rating on the shares with a $275 price target.</p><p>Meanwhile, Citi analyst Atif Malik viewed Nvidia's licensing deal with Groq as a "clear positive.” Citi believes Nvidia has navigated regulatory scrutiny, given that Groq will remain an independent company. It kept a “Buy” rating with a $270 price target.</p><p>Stifel said that Nvidia's deal with Groq could extend AI infrastructure leadership and also kept a “Buy” rating on Nvidia with a $250 price target. UBS also remained bullish on Nvidia shares heading into 2026. It said that it expects appreciation from here to be driven almost by higher earnings estimates.</p><h2 class="st-heading-2">$20 Billion Groq Deal</h2><p>Last week, Groq said that it had entered into a non-exclusive licensing agreement with Nvidia for its inference technology. While the company did not disclose a price, CNBC reported the deal could be valued at $20 billion.</p><p>As per the deal, Nvidia will onboard Groq’s senior management team, including founder Jonathan Ross and President Sunny Madra, to help advance and scale the licensed technology.</p><p>The deal comes at a time when Nvidia is facing stiff competition in the AI inference space from firms like Advanced Micro Devices and Broadcom, among others. Groq specializes in fast AI inference, which will give Nvidia more breathing room on the leaderboard, as it already dominates the market for training AI models.</p><h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2><p>On Stocktwits, retail sentiment around NVDA stock trended in the ‘bearish’ territory amid “normal” message volume.&nbsp;</p><figure class="image"><img style="aspect-ratio:637/64;" src="https://news.stocktwits-cdn.com/nvidia_PNG_0fec69aa4e.webp" alt="On Stocktwits, retail sentiment around NVDA stock trended in the ‘bearish’ territory amid “normal” message volume. " width="637" height="64"></figure><p><br>Shares of Nvidia have gained 36% so far in 2025.&nbsp;<br>&nbsp;</p>

In this photo illustration, the Nvidia logo is seen in the background beside a printed circuit board (PCB). (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Analysts See Nvidia’s Groq Licensing Deal As A Clear Win For AI Leadership

Despite the reported $20 billion price tag, brokerages believe the deal is small relative to Nvidia's scale and long-term earnings power.

Nvidia’s Groq Tie-Up Draws Bullish Calls From Wall Street

<ul class="summary-bullets"><li>The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study.</li><li>JNJ, however, committed to progressing its remaining pipeline of candidates for atopic dermatitis.</li><li>Johnson &amp; Johnson is developing several potential therapies for moderate to severe atopic dermatitis, including NM26, PX128, PX130 and KP-723.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Friday that it is terminating its experimental drug study in the treatment atopic dermatitis due to lack of clinical benefit.</p><p>The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. Atopic dermatitis (AD), commonly called eczema, is a chronic, non-contagious inflammatory skin condition causing intense itching, redness, dryness, and cracking.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study">said</a> that the drug did not achieve the “high-bar” efficacy targets in a planned interim analysis. The drug was, however, well tolerated in the study, the company said.</p><h2 class="st-heading-2">Other Eczema Candidates</h2><p>JNJ committed to progressing its remaining pipeline of candidates for atopic dermatitis on Friday, highlighting that the condition impacts over 100 million people worldwide.</p><p>Johnson &amp; Johnson is developing several potential therapies for moderate to severe atopic dermatitis, including NM26, PX128, PX130 and KP-723. J&amp;J bought the global rights to NM26 from Numab Therapeutics for over $1 billion and acquired PX128 and PX130 through the purchase of Proteologix, both in 2024. KP-723, meanwhile, was developed by Kaken Pharmaceutical and licensed by JNJ in late 204.</p><p>The company does not currently have an FDA-approved drug specifically for eczema on the market.</p><h2 class="st-heading-2">Other Discontinued Trials This Year</h2><p>The discontinued eczema study now joins a longer list of study terminations from JNJ this year. At the onset of 2025, JNJ and partner Sanofi discontinued its E.coli vaccine trial after a study review showed that the vaccine candidate was not sufficiently effective at preventing the E.coli disease compared to placebo.</p><p>In March, the company discontinued a late-stage program evaluating Aticaprant as an adjunctive treatment for major depressive disorder due to insufficient efficacy in the target patient population. More recently, in November, the company discontinued the trial of Posdinemab in early Alzheimer’s disease after the experimental drug failed to achieve statistical significance in slowing clinical decline.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around JNJ fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><figure class="image"><img style="aspect-ratio:621/58;" src="data:image/png;base64,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" width="621" height="58" alt="JNJ’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Dec. 26, 2025 | Source: Stocktwits"><figcaption>JNJ’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Dec. 26, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ stock</a> has gained 43% this year and about 42% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/waymo-leads-on-cities-but-tesla-wins-on-manufacturing-muscle-ark-invest-says/cLetIIfREvv">Waymo Leads On Cities, But Tesla Wins On Manufacturing Muscle, Ark Invest Says</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit

The company said that the drug did not achieve the “high-bar””efficacy targets in a planned interim analysis.

The company said that the drug did not achieve the “high-bar" efficacy targets in a planned interim analysis.


<ul class="summary-bullets"><li>The investigation from the U.S. National Highway Traffic Safety Administration raises concerns over the visibility of the car’s mechanical door releases.&nbsp;</li><li>The petition alleges that the mechanical door release is hidden, unlabeled, and not intuitive to locate in an emergency.&nbsp;</li><li>Tesla’s emergency car handles are also under scrutiny in Europe, while China is reportedly considering banning fully-retractable handles by mid-2027.</li></ul><p>Tesla Inc. (TSLA) is facing a safety investigation from the Office of Defects Investigation (ODI) into the emergency door release controls of its Model 3 sedans.</p><p>The petition cites that the mechanical door release is hidden, unlabeled, and not intuitive to locate during an emergency, as per a release from the U.S. National Highway Traffic Safety Administration (NHTSA).</p><p>The probe is considering about 179,071 model year 2022 vehicles, as per the release.</p><p><a href="https://stocktwits.com/symbol/TSLA/">Shares of TSLA</a> are up about 0.15% in Wednesday’s pre-market trade at the time of writing.</p><h2 class="st-heading-2">Prior Probes</h2><p>In October this year, Dutch safety authority RDW said its regulators will strengthen rules to address concerns about Tesla’s door handle design, ensuring people can safely exit the vehicle in emergencies, as per a Bloomberg report. &nbsp;China is also reportedly considering banning fully-retractable handles by mid-2027.</p><p>Tesla’s 2021 Model Y cars are already under scrutiny by the NHTSA for their electronic door handles, based on nine incidents in which customers were unable to open doors during an emergency.</p><p>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/features/2025-12-22/tesla-door-safety-tied-to-at-least-15-auto-accident-deaths">report from Bloomberg</a>, 15 people have died in car crashes in the US that involved Tesla’s door functionality malfunctioning over the past decade.</p><h2 class="st-heading-2">Design Ethos</h2><p>The emergency door designs are allegedly a consequence of Elon Musk’s strong preference for electrically operated doors over mechanical handles, according to an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/features/2025-12-22/elon-musk-was-warned-of-potential-tesla-door-safety-issues">earlier Bloomberg report</a> citing people familiar with the matter.</p><p>Musk was inspired by Apple’s minimalist design ethos and insisted that everything in the cars, including doors, must be controlled electrically with a button or smart screen, despite concerns from some engineers about the potential safety hazards of electric systems, as per Bloomberg. &nbsp;“The best part is no part,” Musk had reportedly said.</p><p>However, the decision to skip traditional handles in the cars also meant fewer parts, thereby reducing costs and contributing to the final design, according to the people cited in the report.</p><p>Tesla is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-17/tesla-is-redesigning-door-handles-that-drew-scrutiny-over-safety">working on a redesign</a> of its door handles that will look to combine its electronic and manual door-release systems to make it more intuitive, as per the company’s design chief, Franz von Holzhausen.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around TSLA stock remained in the ‘neutral’ territory over the past day, and message volume stayed at ‘high’ levels at the time of writing.</p><figure class="image"><img style="aspect-ratio:1280/148;" src="https://news.stocktwits-cdn.com/Tesla_sentiment_Dec_24_png_02ea04073a.webp" alt="On Stocktwits, retail sentiment around TSLA stock remained in the ‘neutral’ territory over the past day, and message volume stayed at ‘high’ levels at the time of writing." width="1280" height="148"></figure><p>Shares of TSLA have risen by more than 28% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i><br>&nbsp;</p>

A Tesla electric car dealership stands on August 31, 2024 in Erfurt, Germany. 

Tesla Model 3 Faces US Safety Probe Over Emergency Door Release

The U.S. auto safety regulator has opened a defect petition into 179,071 Tesla Model 3 vehicles.

<ul class="summary-bullets"><li>Raytheon will leverage local defense companies in Spain, including Sener, to secure components.</li><li>Patriot is used in air defense strategies in 19 countries, including Germany, the Netherlands, and Romania, which have increased their orders in 2025.</li><li>In November, the U.S. State Department approved the potential sale of Patriots to Ukraine for about $105 million, with RTX being one of the principal contractors.</li></ul><p>Raytheon, an RTX Corp. (<a href="https://stocktwits.com/symbol/RTX">RTX</a>) business unit, has won a $1.7 billion contract to supply four Patriot air and missile defense systems to Spain, the company said on Tuesday.</p><p>The contract marks Spain’s largest Patriot order to date and will include radars, launchers, command-and-control stations, and training equipment. Shares of RTX were up nearly 1% on Tuesday morning at the time of writing.</p><p>Patriot, short for Phased Array Tracking Radar to Intercept on Target, is used in air defense strategies in 19 countries, the company said. It is a ground-based air and missile defense system used to defend against long-range cruise missiles, tactical ballistic missiles, and other air threats.</p><h2 class="st-heading-2">Global Network</h2><p>Raytheon has partnered with local defense companies in Spain, including Sener, to secure components like the electro-mechanical control system used in the GEM-T missile as part of Patriot’s global supply chain network. "Modernizing air and missile defense is vital to Spain's security and sovereignty. Raytheon's work with the Spanish government and local industry will help ensure readiness against evolving threats," said Pete Bata, senior vice president of Global Patriot at Raytheon.</p><p>Spain’s contract comes even as countries like Germany, the Netherlands, and Romania have beefed up orders for Patriot systems in 2025. In November, the U.S. State Department approved the potential sale of Patriots to Ukraine for about $105 million, with RTX being one of the principal contractors.</p><h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2><p>On Stocktwits, retail sentiment around RTX Corp. climbed into the ‘bullish’ territory from ‘neutral’ a day ago, and message volume remained at ‘high’ levels at the time of writing.</p><figure class="image"><img style="aspect-ratio:1272/152;" src="https://news.stocktwits-cdn.com/RTX_sentiment_png_039a502073.webp" alt="On Stocktwits, retail sentiment around RTX Corp. climbed into the ‘bullish’ territory from ‘neutral’ a day ago, and message volume remained at ‘high’ levels at the time of writing." width="1272" height="152"></figure><p>Shares of RTX have gained by more than 61% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The RTX Corporation logo appears on the screen of a smartphone in Reno, United States, on December 10, 2024. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

RTX’s Raytheon Gets Spain’s Largest-Ever Patriot Systems Deal Worth $1.7 Billion 

Spain’s order with Raytheon for four Patriot systems will include radars, launchers, command-and-control stations, and training equipment.

RTX’s Raytheon Gets Spain’s Largest-Ever Patriot Systems Deal Worth $1.7 Billion

Spain’s order with Raytheon for four Patriot systems will include radars, launchers, command-and-control stations, and training equipment.


<ul class="summary-bullets"><li>Bloomberg reported, citing sources familiar with the matter, that Powell McCormick is now considering retaining an advisory role.</li><li>Meta is also not looking to replace her board seat, the report added.</li><li>Powell McCormick and Stripe co-founder Patrick Collison joined the company’s board in April.</li></ul><p>Meta Platforms’ Dina Powell McCormick is stepping down from the board months after joining the company in April.</p><p>Meta said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001326801/000162828025058337/meta-20251219.htm">filing</a> with the Securities and Exchange Commission that Powell McCormick notified the company on Friday that she will resign effective immediately.</p><p>Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-19/meta-board-member-powell-mccormick-resigns-after-eight-months">reported,</a> citing sources familiar with the matter, that she is now considering retaining an advisory role. McCormick is looking to continue working with Meta’s senior leadership team in a broad ranging role that would be focused on investments and strategic counsel, the report said. Meta is also not looking to replace her board seat, the report added.</p><h2 class="st-heading-2">Board Shakeups At Meta</h2><p>Powell McCormick and Stripe co-founder Patrick Collison joined the company’s board in April, as part of the multiple board shuffles at the company. Other new joinees on the board this year include yet another Trump ally and Ultimate Fighting Championship CEO Dana White and Exor CEO John Elkann.</p><p>Powell McCormick is a former top adviser to President Donald Trump and has also served as Assistant Secretary of State for Secretary of State Condoleezza Rice under President George W. Bush. She is currently president of Global Client Services at BDT &amp; MSD Partners. Her husband Dave McCormick is a Republican senator from Pennsylvania.</p><h2 class="st-heading-2">Executive Exits</h2><p>In addition to board members, executives are also in constant flux at Meta. Last month, it was reported that Chief Revenue Officer John Hegeman is leaving the company as well as Business AI unit head Clara Shih. Chief AI scientist Yann LeCun also <a href="https://stocktwits.com/news-articles/markets/equity/why-is-meta-s-yann-le-cun-in-the-spotlight-today/cLPdta0REPo">announced</a> that he is leaving the company at the end of the year to put up his own startup.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around Meta stayed within the ‘bearish’ territory while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/META">META stock</a> has gained 13% this year and by 11% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Dina Powell McCormick speaks at the French-American Foundation - United States Gala 2023 at The Rainbow Room on June 05, 2023 in New York City. (Photo by Sean Zanni/Patrick McMullan via Getty Images)

Meta Sees Another Board Shakeup As Former Trump Adviser Resigns Just Months After Joining

Meta said in a filing with the Securities and Exchange Commission that Powell McCormick notified the company on Friday that she will resign effective immediately.

<ul class="summary-bullets"><li>The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable weight-loss drugs.</li><li>Orforglipron delivered superior weight maintenance when coupled with a healthy diet and physical activity as compared to placebo in the trial.</li><li>According to analyst H.C. Wainwright, the positive study result from Lilly materially de-risks Viking's (VKTX) oral VK2735 program.</li></ul><p>&nbsp;</p><p>Eli Lilly and Company (LLY) said on Thursday that its oral weight loss drug Orforglipron helped weight maintenance in patients who were previously treated with other injectable weight loss therapies in a late-stage study.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html">studied</a> Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable weight-loss drugs Wegovy and Zepbound. While Zepbound is Lilly’s own injectable weight-loss drug, Wegovy is owned by its rival Novo Nordisk. Orforglipron delivered superior weight maintenance when coupled with a healthy diet and physical activity as compared to placebo in the study, the company said.</p><p>The overall safety and tolerability profile of Orforglipron in the trial was consistent with previous studies, the company added.</p><h2 class="st-heading-2">Lilly Awaits FDA Green Light</h2><p>Orforglipron is eligible for a fast-track review by the FDA after it was granted a Commissioner's National Priority Voucher aimed at reducing review time for important drugs in November. Lilly has already submitted an application to the FDA seeking approval for the drug for the treatment of adults with obesity and a decision is expected in early 2026. Lilly’s rival Novo Nordisk is also seeking approval for its oral Wegovy pill, intensifying competition.</p><p>Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. The company is studying the drug in the treatment of type 2 diabetes in addition to obstructive sleep apnea, hypertension, and knee osteoarthritis in adults with obesity.</p><h2 class="st-heading-2">Viking Therapeutics Investors Cheer Lilly’s Trial Data</h2><p>According to analyst H.C. Wainwright, the positive study result from Lilly materially de-risks Viking's (VKTX) oral VK2735 program and its maintenance dosing strategy. The firm believes the data helps reinforce the commercial viability of an oral maintenance approach.</p><p>Wainwright has a ‘Buy’ rating on Viking Therapeutics with a price target of $102 on the shares.</p><p>Viking Therapeutics is currently evaluating several VK2735 dosing options, including a potential once-monthly subcutaneous injection and daily or weekly oral doses, in an ongoing early-stage clinical trial to sustain the initial weight loss achieved after weekly injections. &nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>While shares of LLY traded 3% higher at the time of writing, VKTX rose 1%. On Stocktwits, retail sentiment around LLY stayed within the ‘bullish’ territory over the past 24 hours, while message message volume fell from ‘high’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/LLY">LLY stock</a> has gained 38% this year while <a href="https://stocktwits.com/symbol/VKTX">VKTX</a> has dropped 14%.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-says-starlink-satellite-tumbling-toward-earth-after-anomaly/cLegMrNREr4">SpaceX Says Starlink Satellite Is Tumbling Toward Earth After Anomaly — International Space Station Not At Risk</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics

Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.

<ul class="summary-bullets"><li>B. Riley has maintained a “Buy” rating on the stock.</li><li>The firm told investors in a research note that Lam Research's "superior" memory exposure and Etch leadership offer outsized leverage to accelerating memory wafer fab equipment spend.&nbsp;</li><li>Mizuho has also raised its price target on the stock to $200 from $170.</li></ul><p>Shares of semiconductor equipment maker Lam Research (<a href="https://stocktwits.com/symbol/LRCX">LRCX</a>) rose more than 9% on Thursday after analysts at B.Riley raised their price target on the stock to $195 from $180 and kept a “Buy” rating.&nbsp;</p><p>According to TheFly, B. Riley told investors in a research note that Lam Research's "superior" memory exposure and Etch leadership offer outsized leverage to accelerating memory wafer fab equipment (WFE) spend.&nbsp;</p><p>Shares of Lam Research have more than doubled so far in 2025, driven by rising chip demand and the global adoption of AI.&nbsp;</p><p>Demand for equipment used to make computer chips is expected to rise in the coming years as chipmakers continue to expand capacity to meet increasing demand driven by the adoption of artificial intelligence. It is set to benefit companies like Lam Research, which have been spending heavily to expand the supply of its wafer fab equipment.&nbsp;</p><p>Industry group SEMI said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.semi.org/en/semi-press-release/global-semiconductor-equipment-sales-projected-to-reach-a-record-of-156-billion-dollars-in-2027-semi-reports">report</a> that growth in global sales of semiconductor manufacturing equipment by OEMs is projected to reach a record high of $133 billion in 2025, with projections of $145 billion in 2026 and $156 billion in 2027.</p><h2 class="st-heading-2"><br>Mizuho Take</h2><p>Mizuho analyst Vijay Rakesh, who has also raised the price target on the stock to $200 from $170, said that the firm sees upside to the 2026 wafer fab equipment estimate, and the improving WFE outlook is positive for Lam Research.&nbsp;</p><p>Lam Research has forecasted its second-quarter revenue above estimates, according to the data from Fiscal.ai. It expects second-quarter (Q2) revenue of $5.20 billion, plus or minus $300 million, with the higher end above analyst estimates of $5.23 billion.&nbsp;</p><h2 class="st-heading-2"><br>How Did Stocktwits Users React?</h2><p>On Stocktwits, the retail sentiment around LRCX remained ‘bullish’, and message volume remained ‘high’.&nbsp;<br>&nbsp;</p><figure class="image"><img style="aspect-ratio:798/100;" src="https://news.stocktwits-cdn.com/Capture_5_PNG_dc9038d327.webp" alt="the retail sentiment around LRCX remained ‘bullish’, and message volume remained ‘high’." width="798" height="100"></figure><p>LRCX stock has gained over 125% this year.</p>

In this photo illustration, a person holds a smartphone displaying the logo of Lam Research Corporation (NASDAQ: LRCX) on July 28, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Lam Research Stock Saw A Price Target Hike From B. Riley – What’s The Driving Factor?

B. Riley raised its price target on Lam Research to $195 from $180.

<ul class="summary-bullets"><li>Insmed subsequently decided to discontinue the program with immediate effect.</li><li>The company also announced that it has acquired a new experimental drug called INS1148.&nbsp;</li><li>The new drug adds to the company’s pipeline, the most advanced of which are in pulmonary and inﬂammatory conditions.<br>&nbsp;</li></ul><p>Shares of Insmed Incorporated (INSM) slumped nearly 17% in after-hours trading on Wednesday after the company said that its mid-stage stage study of Brensocatib in patients with chronic rhinosinusitis without nasal polyps did not meet its defined goals.</p><p>While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in the study even at its highest dose of 40 mg, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/insmed-provides-clinical-and-business-update-302645128.html">said.</a> The failed study was conducted across 104 sites globally and enrolled a total of 288 patients</p><p>Insmed subsequently decided to discontinue the program with immediate effect. "While we are disappointed in the results, they provided us with a clear answer,” Chief Medical Officer of Insmed Martina Flammer said.</p><h2 class="st-heading-2">Gearing Forward With New Acquisition</h2><p>Bridgewater, New Jersey-headquartered Insmed also announced on Wednesday that it has acquired a new experimental drug called INS1148 with potential in addressing respiratory and immunological and inflammatory diseases. The company now plans to advance mid-stage development plans for the drug initially in interstitial lung disease and moderate-to-severe asthma.</p><p>The drug was developed by privately held pharmaceutical company Opsidio and formerly known as OpSCF.</p><p>The drug adds to the company’s pipeline, the most advanced of which are in pulmonary and inﬂammatory conditions.</p><h2 class="st-heading-2">Pipeline And Approvals</h2><p>Last month, the European Commission approved the company’s Brinsupri for the treatment of a chronic and progressive lung disease non-cystic fibrosis bronchiectasis in patients 12 years of age and older. It is the only approved treatment for the condition in the European Union.</p><p>Brinsupri was approved by the U.S. Food and Drug Administration for the treatment of the condition in August. Non-cystic fibrosis bronchiectasis is a chronic lung condition where airways become permanently widened and damaged, leading to a vicious cycle of mucus buildup, infection, inflammation, and cough with sputum.</p><h2 class="st-heading-2">Analyst Optimism Dampened</h2><p>Cantor Fitzgerald had raised the price target on Insmed to $230 from $216 on Wednesday in anticipation of the trial results. The analyst, who kept an ‘Overweight’ rating on the shares, had termed the study results as the stock’s “next important catalyst” and had said that it sees a "good chance" of Brensocatib showing a benefit in chronic rhinosinusitis without nasal polyps.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around Insmed stayed within the ‘bullish’ territory over the past 24 hours while message volume stayed at 'high' levels.</p><p><a href="https://stocktwits.com/symbol/INSM">INSM stock</a> has nearly tripled this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/archer-eyes-deploying-air-taxis-in-major-us-cities-amid-short-sellers-no-fly-concerns/cLeOuYiREAG">Archer Eyes Deploying Air Taxis In Major US Cities Backed By Government Push Amid Short Seller’s No-Fly Concerns</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit

While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg. 

<ul class="summary-bullets"><li>Shield Technology Partners is a new IT Services platform backed by Thrive Holdings, a tech investment firm.</li><li>Jim Siders will be departing Palantir after 12 years at the company, most recently as its chief information officer.&nbsp;</li><li>Shield works with seven companies, mostly small and mid-sized businesses, and is expected to generate more than $100 million in revenue this year.</li></ul><p>Palantir Technologies Inc.’s (PLTR) Chief Information Officer, Jim Siders, will be leaving the company after 12 years to become the Chief Executive Officer at Shield Technology Partners.</p><p>Shield Technology Partners is a new IT Services platform backed by Thrive Holdings, an investment firm with stakes in tech companies such as OpenAI, Stripe, and Databricks. Shield will partner with Thrive Holdings and OpenAI to integrate artificial intelligence into its partner businesses.</p><p>According to a CNBC report, Thrive stated Shield is expected to generate more than $100 million in revenue this year and currently works with seven companies, primarily small and mid-sized businesses.</p><p>“AI is rewriting the economics of service delivery at the exact time IT service providers are rethinking how they operate," stated Siders. “Shield is this incredible combination of long-term vision, technological expertise, and operational know-how that I think makes it perfect for this moment in time. We have lightning in a bottle.”</p><h2 class="st-heading-2">Journey At Palantir</h2><p>Jim Siders started his journey at Palantir as an IT helpdesk engineer and rose to chief information officer, overseeing global IT operations, infrastructure, and business applications in 2022.</p><p>Siders oversaw Palantir at a time when the company’s revenue grew over $4 billion. He also led the setup of a federated structure that aligned technology and data workflows more directly with business value. Shares of <a href="https://stocktwits.com/symbol/PLTR">PLTR</a> are up over 147% in the past year.</p><p>“Jim has been one of the early advocates for getting engineers to work directly alongside their customers,” said Anuj Mehndiratta, a member of the Thrive Holdings founding team. “He has been in the shoes of our partners and understands intuitively what their customers want.”</p><p>Palantir has yet to make an official announcement of Siders’ departure. Meanwhile, the company has announced a three-year renewal of its contract with the DGSI, France's domestic intelligence agency.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, the retail sentiment around PLTR remained ‘neutral’ over a week, and message volume stayed at ‘normal’ levels at the time of writing.</p><figure class="image"><img style="aspect-ratio:1261/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_8_09_47_PM_png_5c84c88df3.webp" alt="On Stocktwits, the retail sentiment around PLTR remained ‘neutral’ over a week, and message volume stayed at ‘normal’ levels at the time of writing." width="1261" height="153"></figure><p>Shares of PLTR are up over 1.8% on Monday morning at the time of writing and have surged over 148% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i><br>&nbsp;</p>

A computer with the acronym AI for Artificial Intelligence.

Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business

im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment. 

JGRO
JPMorgan Active Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest JGRO News

JGROJPMorgan Active Growth ETF